Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716716 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIa Study of FIXFc in Hemophilia B Patients
A Phase 1 study, sponsored by Bioverativ Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00716716 is a Phase 1 study that has completed, run by Bioverativ Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT00716716, a Phase 1 study, has completed, sponsored by Bioverativ Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.
Interventions
- DRUG rFIXFc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716716
The ClinicalTrials.gov registry entry for NCT00716716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFIXFc is the first listed.
NCT00716716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716716 about?
NCT00716716 is a clinical study titled "Phase I/IIa Study of FIXFc in Hemophilia B Patients". The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.
What is the current status of trial NCT00716716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00716716?
The interventions under investigation include: rFIXFc (DRUG).
Who is sponsoring clinical trial NCT00716716?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.